CN1485320A - Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine - Google Patents
Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine Download PDFInfo
- Publication number
- CN1485320A CN1485320A CNA021438331A CN02143833A CN1485320A CN 1485320 A CN1485320 A CN 1485320A CN A021438331 A CNA021438331 A CN A021438331A CN 02143833 A CN02143833 A CN 02143833A CN 1485320 A CN1485320 A CN 1485320A
- Authority
- CN
- China
- Prior art keywords
- compound
- ether
- tert
- hydroxyl
- phenylpiperidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
A method of preparing a heterocyclic compound, especially containing a sixmembered ring, which contain N atom as the only one heterocyclic atom and won't fuse with other rings. It comprises: taking natural L-glutamate as the raw material, synthesizing the compound 9, then getting the important intermediate compound of L-733060, that is, (2S, 3S)-2, preparing an P-antagonist L-733060 from the compound (2S, 3S)-2 by a known method. All reagents are common, the optical purity of L-733060 from the compound (2S, 3S)-2 could be 97%.
Description
(1) technical field
The present invention relates to a kind of heterogeneous ring compound, especially contain six-membered ring, do not condense, with the synthetic method of a nitrogen-atoms as the heterogeneous ring compound of unique ring hetero atom with other ring.
(2) background technology
Pathological research shows that neurokinin P material is pathogenic relevant with diseases such as rheumatoid arthritis, asthma.The focus that development is efficient, the P substance antagonist of low toxicity becomes people's research wherein develops non-peptide P substance antagonist, is mainly the 2-phenylpiperidine, and for example L-733060 has become the interested field of people.U.S. Merk company has used year surplus in the of 10 to be devoted to the research and development of this class medicine.European patent EP 0528495 A1 at first discloses in 1993 by what Merk sharpand Dohme research laboratory applied for and has prepared 3-hydroxyl-2-Phenylpiperidine by phenyl aldehyde and 4-nitro methyl-butyrate, and then prepare the method for P substance antagonist L-733060, its key step is that phenyl aldehyde and the condensation of 4-nitro methyl-butyrate get 5-nitro-2-oxo-piperidine, the latter through ozonize, lithium aluminium hydride reduction get racemization the 3-hydroxyl-the 2-Phenylpiperidine is suitable, trans isomer is 3: 1 mixture.Form salt with para-toluenesulfonate again, isolate cis-isomeride, use at last (-)-Mountain-spring stone diphenyl phthalate splits by recrystallization, just can obtain important intermediate (2S, 3S)-3-hydroxyl-2-Phenylpiperidine (2S, 3S)-1.This intermediate just can make L-733060 (Bioorg.Med.Chem.Lett., 4,2545-2550,1994) through three steps again.Its synthetic route is as follows:
Though it is leading that the cis that this method obtains accounts for, but still be racemic modification, must through split just can obtain optically pure intermediate (2S, 3S)-1.
1999, to be raw material also can make suitable, anteiso-object through sharpless AD reaction to usefulness 5-such as H.Stadler nitrine-1-benzene pentanone is 3-hydroxyl-2-Phenylpiperidine (Heterocycles of 4: 1,51,1067-1071,1999), though this method can obtain optically active intermediate, the ee value is on the low side (83%ee).
In the same year, usefulness erythros (2S) such as O.Calvez-1-benzyl-2-hydroxyphenyl tetramethyleneimine is a raw material, can make intermediate (2S, 3S)-2 (TL, 40,7099-7100,1999) of enantiomer-pure through reactions such as ring expansions.This method has a step to need use the Swern oxidation, and the L-selectride reduction obtains that (2S, 3S)-2, because of the ketone (2S)-3 of oxidation generation, racemization easily takes place (alkaline condition) under this reaction conditions, so operate wayward then.Relevant step is as follows:
Recently, J.Lee has reported with phenylacetylene and 1-chloro-3-N-PROPYLE BROMIDE to be that raw material is through multistep synthetic enantiomer-pure intermediate (2S, method 3S)-2 (TL, 42,6223-6225,2001).
(3) summary of the invention
It is raw material with natural compounds L-L-glutamic acid cheap, that be easy to get that purpose of the present invention aims to provide a kind of, the synthetic enantiomer-pure of highly-solid selectively (2S, 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine.
Concrete synthetic route of the present invention is as follows, and among narration below and the embodiment subsequently, specific synthetic product is according to the numbering in the structural formula, represents with Arabic numerals.R or S represent the absolute configuration of compound, and Ph represents phenyl, and PMB represents that t-Bu represents the tertiary butyl to a methoxy-benzyl, and TBDPS represents that tert-butyl diphenyl is silica-based, and BOC represents tert-butoxycarbonyl.
Under step 1 normal temperature, L-L-glutamic acid and dilute sulphuric acid and sodium nitrite solution reaction 10～20h get compound 4.
Step 2 is under 35～70 ℃, and the excessive carboxylic acid halides of pressure reducing and steaming behind compound 4 and a kind of carboxylic acid halides reaction 1～8h then, is a solvent with the methylene dichloride, reacts 2～6h with a kind of primary amine at-78～25 ℃, obtains compound 5 through recrystallization.Here the carboxylic acid halides that refers to mainly refers to sulfur oxychloride, acetyl chloride, and primary amine refers to aliphatic amide, aromatic amine, particularly methylamine, benzylamine, to a methoxybenzylamine.
Step 3 compound 5 under-78～0 ℃, with a kind of alkali reaction 1～15h, obtains compound 6 behind concentrating under reduced pressure and recrystallization in a kind of ether.Said ether is C
2～C
4Aliphatic ether, alicyclic ether is meant ether and tetrahydrofuran (THF) especially, said alkali is meant the sodium salt and the sylvite of organolithium reagent, metal hydride, alcohol.Particularly lithium diisopropyl amido, sodium hydride, sodium ethylate, potassium tert.-butoxide.
Step 4 compound 6 is in a kind of halohydrocarbon or ether solvent, under 0～30 ℃, with tert-butyl diphenyl chlorosilane and a kind of alkali reaction 10～20h, through dichloromethane extraction, drying, concentrate, obtain compound 7 behind the silica gel column chromatography.Said halohydrocarbon is meant C
1～C
4Halohydrocarbon, particularly methylene dichloride, trichloromethane; Said ether is meant C
2～C
4Aliphatic ether, alicyclic ether, be meant ether and tetrahydrofuran (THF) especially; Said alkali is tertiary amine, particularly pyridine and triethylamine.
Step 5 compound 7 in a kind of alcohol that contains halohydrocarbon, under-30～0 ℃, with sodium borohydride reaction 5～60min, through dichloromethane extraction, drying, concentrate, recrystallization obtains compound 8.Said halohydrocarbon is meant C
1～C
4Halohydrocarbon, particularly methylene dichloride, trichloromethane; Said alcohol is meant C
1～C
4Fatty Alcohol(C12-C14 and C12-C18), particularly methyl alcohol, ethanol.
Step 6 compound 8 in a kind of halogenated hydrocarbon or ether solvent, under 0～45 ℃, with a kind of Lewis acid reaction 24～96h, through saturated sodium bicarbonate neutralization, dichloromethane extraction, drying, concentrate, recrystallization obtains compound 9.Said halohydrocarbon is meant C
1～C
4Halohydrocarbon, particularly methylene dichloride, trichloromethane; Said ether is meant C
2～C
4Aliphatic ether, alicyclic ether, be meant ether and tetrahydrofuran (THF) especially; Said Lewis acid is meant the compound of boracic or aluminium, is meant boron trifluoride ether solution especially.
Step 7 compound 9 down closes dimethyl sulphide reduction 1～15h with Lithium Aluminium Hydride or borine at 0～60 ℃ in ether or tetrahydrofuran (THF), preferably in tetrahydrofuran (THF), 50 ℃ react 1h down.Successively behind hydro-oxidation sodium water solution and the water, filter, concentrate and silica gel column chromatography after compound 10.
Step 8 compound 10 in a kind of alcohol, through a kind of palladium catalyst catalysis, the nitrogen atmosphere of 1～3atm and 15～35 ℃ down with (BOC)
2O reacts 24～96h.Filter, concentrate and silica gel column chromatography after obtain (2S, 3S)-2.Said palladium catalyst mainly is meant palladium one carbon, palladium hydroxide one carbon.
The present invention is a raw material with inexpensive, facile natural compounds L-L-glutamic acid, high enantioselectivity ground has synthesized compound 9, thereby made the important intermediate compound (2S of synthetic L-733060,3S)-2, (2S 3S)-2 just can make P substance antagonist L-733060 through known method to compound again.Each step operation of the present invention separates simple, and it is higher that each goes on foot productive rate, and agents useful for same is common reagent.(2S 3S)-2 again can be up to 97%ee through the synthetic optical purity that obtains L-733060 of three steps from present method synthetic compound.
(4) embodiment
Further specify the present invention with embodiment below.
Embodiment 1
Step 1 is synthesized (S)-2,3,4,5-tetrahydrochysene generation-5-oxo-2-furancarboxylic acid 4
(22.406g adds distilled water (150mL) in three neck round-bottomed flasks 0.15mol), drips 1M H under 35 ℃ simultaneously toward filling L-L-glutamic acid
2SO
4(91.5mL is 0.092moL) with 2M NaNO
2(91.5mL, 0.19moL), stirring at normal temperature is crossed liquid.Concentrate, and with acetone (5 * 100mL) refluxing extraction.Merge acetone extract, concentrate, get compound 4, be faint yellow viscous liquid.Compound 4 directly carries out next step reaction without further purification.
Step 2 is synthesized (S)-N-(4-methoxy-benzyl)-2,3,4,5-tetrahydrochysene generation-5-oxo-2-furoylamide 5
Get compound 4 (6.263g, 0.048mol) with thionyl chloride (10.6mL, 0.15mmoL) one arise from 40 ℃ stir 8h after, the thionyl chloride that pressure reducing and steaming is excessive.Under the nitrogen protection, add anhydrous methylene chloride (40mL), triethylamine (10mL, 0.072moL).Under-30 ℃, slowly dropping contains a methoxybenzylamine (6.3mL, methylene dichloride 0.048moL) (8mL) solution, continuation constant temperature stirring 6h.Add water (20mL), tell organic phase, water extracts with methylene dichloride (20mL * 3).Merge organic phase, and use the saturated common salt water washing, anhydrous sodium sulfate drying concentrates.Gained brown solid activated carbon decolorizing is used re-crystallizing in ethyl acetate again, mother liquor with silica gel column chromatography separate (ethyl acetate: sherwood oil=3: 1), compound 5,8.38g, colourless acicular crystal, productive rate 70%, m.p.92～93 ℃.
Step 3 is synthesized (S)-3-hydroxyl-1-(4-methoxy-benzyl)-2,6-dioxopiperidine 6
Under the nitrogen protection; under-78 ℃; freshly prepd lithium diisopropyl amido (27.09mmol) tetrahydrofuran (THF) (10mL) solution is slowly splashed into compound 5 (7.100g; 28.51mmol) tetrahydrofuran (THF) (40mL) solution in ,-78 ℃ stir 1.5h after, add saturated ammonia chloride (10mL); water (10mL); with ethyl acetate (20mL * 3) extraction, anhydrous sodium sulfate drying concentrates.Gained white solid re-crystallizing in ethyl acetate, mother liquor with silica gel column chromatography separate (ethyl acetate: sherwood oil=1: 1) compound 6,3.763g colourless acicular crystal, productive rate 53%, m.p.98～99 ℃.
Step 4 is synthesized (S)-3-tert-butyl diphenyl siloxy-1-(4-methoxy-benzyl)-2,6-dioxopiperidine 7
Under the nitrogen protection, toward compound 6 (4.100g, 16.47mmol) and imidazoles (2.23g in methylene dichloride 32.93mmol) (40mL) solution, slowly drips tert-butyl diphenyl chlorosilane (4.7mL, methylene dichloride 18.10mmol) (5mL) solution.Behind the stirring at room 12h, add water (20mL), tell organic phase, water extracts with methylene dichloride (20mL * 3).Merge organic phase, anhydrous sodium sulfate drying concentrates.Crude product separates (ethyl acetate: sherwood oil=1: 8), get compound 7,7.538g, colourless viscous liquid, productive rate 94% with silica gel column chromatography.
Step 5 is synthesized (S)-5-tert-butyl diphenyl siloxy-6-hydroxyl-1-(4-methoxy-benzyl)-2-piperidone 8
(4.300g 8.83mmol) is dissolved in the anhydrous methanol (30mL), under-20 ℃, with sodium borohydride (1.006g, 26.47mmol) reaction 50min with compound 7.Add cold saturated sodium bicarbonate (10mL) and cold saturated aqueous common salt (10mL), cold methylene dichloride (20mL) again.Tell organic phase, water extracts with methylene dichloride (20mL * 3).Merge organic phase, with a spot of saturated common salt washing, anhydrous sodium sulfate drying concentrates.The crude product re-crystallizing in ethyl acetate, mother liquor separates (ethyl acetate: sherwood oil=1: 2), get compound 8 with silica gel column chromatography, 3.454g, colourless acicular crystal, productive rate 72%, m.p.165～166 ℃ (cis, main steric isomer) 174.5～175.5 ℃ (trans).This conversion zone selectivity is 9.5: 1, and stereoselectivity is 82: 18.
Step 6 synthetic (5S, 6S)-1-(4-methoxy-benzyl)-5-hydroxyl-6-phenyl-2-piperidone 9
Under the nitrogen protection, (1.000g 2.05mmol) is dissolved in the methylene dichloride (20mL) with compound 8.Under 40 ℃, with etherate of trifluoroboron (2.5mL, 20.25mmol) reaction 24h.Under the ice-water bath, slowly drip saturated sodium bicarbonate aqueous solution (5mL).Tell organic phase, water extracts with methylene dichloride (5mL * 3).Merge organic phase, room temperature continues to stir 24h.Add water (10mL), neutralize with 10% aqueous sodium hydroxide solution.Tell organic phase, water extracts with methylene dichloride (10mL * 3).Merge organic phase, anhydrous sodium sulfate drying concentrates.Crude product separates (ethyl acetate: sherwood oil=2: 1) get compound 9,0.515g, colourless acicular crystal, productive rate 81% with ethyl acetate/petroleum ether=3: 1 recrystallizations, mother liquor with silica gel column chromatography.m.p.172.5～173.5℃。
Step 7 synthetic (2S, 3S)-1-(4-methoxy-benzyl)-3-hydroxyl-2-Phenylpiperidine
Under the nitrogen protection, (460mg, anhydrous tetrahydro furan 1.48mmol) (4mL) solution splash into Lithium Aluminium Hydride, and (281mg is 7.40mmol) and in the mixed solution of anhydrous tetrahydro furan (6mL) will to be dissolved with compound 9.Be heated to 50 ℃, stir 1h.Be chilled to 0 ℃, drip 10% sodium hydroxide solution (0.6mL) and water (0.2mL) successively.Diatomite filtration, washed with dichloromethane, drying concentrates.Crude product purification by silica gel column chromatography (ethyl acetate: sherwood oil=1: 4) get compound 10,355mg, weak yellow liquid, productive rate 81%.This liquid is set to faint yellow solid for a long time, gets faint yellow needle-like crystal with acetone recrystallization, m.p.106～107 ℃.
Step 8 synthetic (2S, 3S)-1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine (2S, 3S)-2
(136mg 0.46mmol) is dissolved in the anhydrous methanol (4mL) compound 10, adds (BOC)
2O (0.32mL, 1.40mmol).Under the room temperature, in nitrogen atmosphere with 20% palladium hydroxide, one carbon (110mg) catalyzed reaction 48h.With filter paper elimination palladium hydroxide one carbon, washed with dichloromethane, concentrate.Crude product with silica gel column chromatography separate (methylene dichloride: acetone=20: 1), compound (2S, 3S)-2,112mg, colourless oil liquid, productive rate 88%.
Embodiment 2
Step 1 is synthesized (S)-N-(4-methoxy-benzyl)-2,3,4,5-tetrahydrochysene generation-5-oxo-2-furoylamide (S)-5
The preparation of compound 4 is with embodiment 1, and compound 5 is made by the method for 4 preparations 5 by embodiment 1, and promptly compound 4 stirs 4h with thionyl chloride in 65 ℃.The thionyl chloride that pressure reducing and steaming is excessive.Under the nitrogen protection, add anhydrous methylene chloride, triethylamine and to a methoxybenzylamine.0 ℃ is stirred 4h down, gets compound 5, productive rate 65%.
Step 2 is synthesized (S)-3-hydroxyl-1-(4-methoxy-benzyl)-2,6-dioxopiperidine (S)-6
Under the nitrogen protection, compound 5, (7.100g, 28.51mmol) and potassium tert.-butoxide (1.600g, mixture 14.29mmol) adds down anhydrous tetrahydro furans (60mL) at-40 ℃, under this temperature, stirs 3h.Add ammonium chloride saturated solution (20mL), with ethyl acetate (30mL * 3) extraction.Merge organic phase, a small amount of saturated common salt washing, anhydrous sodium sulfate drying concentrates, and recrystallization gets compound 6, productive rate 90% behind the mother liquor silica gel column chromatography.
Step 3 is synthesized (S)-3-tert-butyl diphenyl siloxy-1-(4-methoxy-benzyl)-2,6-dioxopiperidine (S)-7
Press the method for embodiment 1 by compound 6 inhibition and generation compounds 7, make solvent with tetrahydrofuran (THF), stirring at room 5h gets (S)-7, productive rate 87%.
Step 4 is synthesized (S)-5-tert-butyl diphenyl siloxy-6-hydroxyl-1-(4-methoxy-benzyl)-2-piperidone
Press the method for embodiment 1 by compound 7 inhibition and generation compounds 8, with methyl alcohol: the mixed solution of methylene dichloride=5: 1 is a solvent, under-20 ℃, stirs 30min, (S)-8, productive rate 80%, regioselectivity and stereoselectivity are constant substantially.
Step 5 synthetic (5S, 6S)-1-(4-methoxy-benzyl)-5-hydroxyl-6-phenyl-2-piperidone (5S, 6S)-9
Press the method for embodiment 1 by compound 8 inhibition and generation compounds 9, compound 8 at room temperature stirs 48h with etherate of trifluoroboron solution, make (5S, 6S)-9, productive rate 76%.
Step 6 synthetic (2S, 3S)-1-(4-methoxy-benzyl)-3-hydroxyl-2-Phenylpiperidine (2S, 3S)-10
Under the nitrogen protection, (1.100g 3.54mmol) is dissolved in the anhydrous tetrahydro furan (15mL) compound 9, slowly drips borine under the ice-water bath and closes dimethyl sulphide solution (1mL).Stirring at room 15h.Add water (10mL), with methylene dichloride (10mL * 3) extraction, anhydrous sodium sulfate drying concentrates.Crude product with silica gel column chromatography separate compound 10,0.872g, productive rate 83%.
Step 7 synthetic (2S, 3S)-1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine (2S, 3S)-2
(2S, method 3S)-2 are solvent with the dehydrated alcohol, and under the room temperature and in the nitrogen atmosphere, compound 10 is under the catalysis of palladium hydroxide one carbon, with (BOC) by compound 9 inhibition and generation compounds to press embodiment 1
2The O reaction, (2S, 3S)-2, productive rate 85%.
Embodiment 3
Step 1 (S)-4 → (S)-5
The preparation of compound 4 is pressed the method for embodiment 1 by system (S)-5, (S)-4 with embodiment 1, and compound 4 stirs 8h with Acetyl Chloride 98Min. down at 40 ℃, and all the other operations are identical, make (S)-5, productive rate 50%.
Step 2 (S)-5 → (S)-6
Under the nitrogen protection, (347mg, tetrahydrofuran (THF) 1.40mmol) (3mL) solution join in the mixed solution of sodium hydride (53mg, 60%) and tetrahydrofuran (THF) (10mL) will to be dissolved with compound 5.Stir 15h down at 0 ℃.In reaction mixture, add saturated ammonium chloride solution (2mL) successively, water (5mL), with ethyl acetate (10mL * 3) extraction, anhydrous sodium sulfate drying concentrates, and recrystallization, mother liquor are crossed post and are got 138mg compound 6, productive rate 40%.
Step 3 (S)-6 → (S)-7
Compound 7 makes by the method for embodiment 1
Step 4 (S)-7 → (S)-8
Compound 8 makes by the method for embodiment 1.
Step 5 (S)-8 → (S)-9
Compound 9 makes by the method for embodiment 1.
Step 6 (5S, 6S)-9 → (2S, 3S)-10
Compound 10 is pressed the method for embodiment 1, makes solvent with anhydrous diethyl ether, and 40 ℃ are reacted 3h down and make compound 10.
Step 7 (2S, 3S)-10 → (2S, 3S)-2
Compound 10 is pressed the method for embodiment 2, makes catalyzer with palladium one carbon, normal-temperature reaction 72h, make compound (2S, 3S)-2.
Embodiment 4
Step 1～7 are identical with step 1～7 of embodiment 3.
Under step 8 nitrogen protection, (60%NaH is in mineral oil, and 15mg adds DMF (0.5mL) in single neck round-bottomed flask 0.63mmol) toward filling sodium hydride.Under the ice-water bath, slowly dropping contains compound (2S, 3S)-2 (60mg, DMF 0.22mmol) (1mL) solution.Slowly drip 3,5-bis trifluoromethyl benzyl bromine (60 μ L, DMF 0.33mmol) (0.2mL) solution behind the reaction 0.5h under the room temperature.Stirring at room under ice-water bath, adds water (10mL) two days later, with ether (3 * 3mL) extractions.Merge organic phase, (2mL) washes with saturated aqueous common salt, and anhydrous sodium sulfate drying concentrates.Separate (ether/sherwood oil=1: 8) with silicagel column and get compound 11,85mg is colourless oil liquid, productive rate 78%.
Under step 9 nitrogen protection, (50mg adds anhydrous methylene chloride (1mL) in single neck round-bottomed flask 1.0mmol) containing compound 11.Under the ice-water bath, and the dropping trifluoroacetic acid (80 μ L, 1.04mmol).Stirring at room two days later, the mixed solution concentrating under reduced pressure.Add water (2mL), be neutralized to pH=8, with methylene dichloride (5mL * 3) extraction with the 1M sodium bicarbonate.Merge organic phase, use anhydrous sodium sulfate drying, concentrate, separate (CH through silicagel column
2Cl
2/ MeOH/NH
3H
2O=100/3/1) get compound L-733060,37mg is colourless oil liquid, productive rate 78%.
The preparation method of L-733060 hydrochloride is: under the nitrogen protection, in ice-water bath, drip acetyl chloride (0.1mL) in the single neck round-bottomed flask that fills anhydrous methanol (1mL).Get the 0.5mL aforesaid liquid, slowly splash into and contain compound L-733060 (37mg is in methyl alcohol 0.092mmol) (1mL) solution.Vibration a moment, concentrate the L-733060 hydrochloride, be a white solid.[α]
D 28＝+84.490(C＝0.8，MeOH)，m.p.213～215℃。The ee value is 97%.
Claims (9)
1, a kind of synthetic generated in high enantiomeric purity (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that synthetic route is as follows:
Its concrete synthesis step is as follows:
Under step 1 normal temperature, make compound 4 behind L-L-glutamic acid and dilute sulphuric acid and the Sodium Nitrite reaction 10～20h;
Step 2 is under 35～70 ℃, the excessive carboxylic acid halides of pressure reducing and steaming behind compound 4 and a kind of carboxylic acid halides reaction 1～8h, then, with the methylene dichloride is solvent, react 2～6h with a kind of primary amine at-70～25 ℃, obtain compound 5 through recrystallization, said carboxylic acid halides is sulfur oxychloride, acetyl chloride, and said primary amine is aliphatic amide, aromatic amine;
Step 3 compound 5 under-78～0 ℃, with a kind of alkali reaction 1～15h, obtains compound 6 behind concentrating under reduced pressure and recrystallization in a kind of ether, said ether is C
2～C
4Aliphatic ether, alicyclic ether, said alkali are the sodium salt or the sylvite of organolithium reagent, metal hydride, alcohol;
Step 4 compound 6 is in a kind of halohydrocarbon or ether solvent, and under 0～30 ℃, with tert-butyl diphenyl chlorosilane and a kind of alkali reaction 10～20h, through dichloromethane extraction, drying, concentrate, obtain compound 7 behind the silica gel column chromatography, said halohydrocarbon is meant C
1～C
4Halohydrocarbon, said ether is C
2～C
4Aliphatic ether, alicyclic ether, said alkali is tertiary amine;
Step 5 compound 7 is in a kind of alcohol that contains halohydrocarbon, and under-30～0 ℃, with sodium borohydride reaction 5～60min, through dichloromethane extraction, drying concentrates, and recrystallization obtains compound 8, and said halohydrocarbon is C
1～C
4Halohydrocarbon, said alcohol is C
1～C
4Fatty Alcohol(C12-C14 and C12-C18);
Step 6 compound 8 under 0～45 ℃, with a kind of Lewis acid reaction 24～96h, neutralizes through saturated sodium bicarbonate in a kind of halogenated hydrocarbon or ether solvent, dichloromethane extraction, and drying concentrates, and recrystallization obtains compound 9, and said halohydrocarbon is meant C
1～C
4Halohydrocarbon, said ether is meant C
2～C
4Aliphatic ether, alicyclic ether, said Lewis acid is meant the compound of boracic or aluminium;
Step 7 compound 9 down closes dimethyl sulphide reduction 1～15h with Lithium Aluminium Hydride or borine at 0～60 ℃ in ether or tetrahydrofuran (THF), behind hydro-oxidation sodium water solution and the water, filter successively, concentrate and silica gel column chromatography after get compound 10;
Step 8, compound 10 in a kind of alcohol, through a kind of palladium catalyst catalysis, the nitrogen atmosphere of 1～3atm and 15～35 ℃ down with (BOC)
2O reacts 24～96h, filters, concentrate and silica gel column chromatography after obtain that (2S, 3S)-2, said alcohol is C
1～C
4Fatty Alcohol(C12-C14 and C12-C18), said palladium catalyst are meant palladium one carbon or palladium hydroxide one carbon.
2, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said primary amine is a methylamine to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1, benzylamine or to a methoxybenzylamine.
3, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said ether is ether or tetrahydrofuran (THF) to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
4, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said alkali is lithium diisopropyl amido in the step 3, sodium hydride, sodium ethylate, potassium tert.-butoxide to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
5, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said halohydrocarbon is a methylene dichloride in the step 3, trichloromethane to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
6, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said alkali is pyridine in the step 4, triethylamine to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
7, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said alcohol is methyl alcohol, ethanol to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
8, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that said Lewis acid is an etherate of trifluoroboron solution in the step 6 to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1.
9, (2S 3S)-method of 1-tert-butoxycarbonyl-3-hydroxyl-2-Phenylpiperidine, is characterized in that in the step 7 compound 9 in tetrahydrofuran (THF) to a kind of synthetic generated in high enantiomeric purity as claimed in claim 1,50 ℃ of reaction 1h down.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021438331A CN1189458C (en) | 2002-09-28 | 2002-09-28 | Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021438331A CN1189458C (en) | 2002-09-28 | 2002-09-28 | Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1485320A true CN1485320A (en) | 2004-03-31 |
| CN1189458C CN1189458C (en) | 2005-02-16 |
Family
ID=34148335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021438331A Expired - Fee Related CN1189458C (en) | 2002-09-28 | 2002-09-28 | Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1189458C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110372633A (en) * | 2019-08-01 | 2019-10-25 | 台州学院 | A method of the carbon-based derivative reduction of catalysis iminodibenzyl |
| CN115557985A (en) * | 2022-12-06 | 2023-01-03 | 成都泰蓉生物科技有限公司 | Method for selectively cracking C-S bond in thioether to form silane |
-
2002
- 2002-09-28 CN CNB021438331A patent/CN1189458C/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110372633A (en) * | 2019-08-01 | 2019-10-25 | 台州学院 | A method of the carbon-based derivative reduction of catalysis iminodibenzyl |
| CN110372633B (en) * | 2019-08-01 | 2022-11-04 | 台州学院 | Method for catalyzing reduction of iminodibenzyl carbonyl derivative |
| CN115557985A (en) * | 2022-12-06 | 2023-01-03 | 成都泰蓉生物科技有限公司 | Method for selectively cracking C-S bond in thioether to form silane |
| CN115557985B (en) * | 2022-12-06 | 2023-03-10 | 成都泰蓉生物科技有限公司 | Method for selectively cracking C-S bond in thioether to form silane |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1189458C (en) | 2005-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ikawa et al. | Preparation and regioselective Diels–Alder reactions of borylbenzynes: Synthesis of functionalized arylboronates | |
| ES2426399T3 (en) | Nebivolol Formate | |
| CN1038032C (en) | {(Benzodioxan, benzofuran or benzopyran) alkylamino} alkyl substituted guanidines | |
| Keck et al. | Alkaloid synthesis via intramolecular ene reaction. 2. Application to dl-mesembrine and dl-dihydromaritidine | |
| CN1263726C (en) | Process and intermediates to prepare latanoprost | |
| CN1045957C (en) | Heterocyclic compounds, their use and preparation | |
| CN1263753C (en) | Method for synthetizing orixine and RU-19110 intermediate | |
| CN1189458C (en) | Method for producing high purity antimer of (2s,3s)-1-tert-butoxy carbonyl-3-hydroxy-2-phenyl piperidine | |
| CN1297557C (en) | Preparation of spirocyclic template compound | |
| Degnan et al. | Enantioselective synthesis of rigid 2-aminotetralins. Utility of silicon as an oxygen and nitrogen surrogate in the tandem addition reaction | |
| CN1183137C (en) | Synthesis method of [3aS, 6aR]-1,3-dibenzyl-tetrahydro-4H-fruo [3,4-d]-imidazolyl-2,4 [1H]-diketone [I] | |
| CN1882543A (en) | Process for preparation of chiral amlodipine salts | |
| CN1329606A (en) | Chroman derivatives | |
| Honda | Investigation of innovative synthesis of biologically active compounds on the basis of newly developed reactions | |
| Majewski et al. | Stereoselective synthesis of hydroxyindolizidines via sparteine-assisted deprotonation of N-Boc-pyrrolidine | |
| CN110317170B (en) | Green synthesis method of 3-phenanthridinyl propyl formate compound | |
| CN114163445A (en) | Raatinib intermediate and preparation method thereof | |
| CN1051765C (en) | Stereoselective synthesizing process for enantiomorph pure 3-amino-1,2-twice substituted pyrrolidine | |
| CN1341113A (en) | Process for production of paroxetine | |
| CN1162313A (en) | Substituted tetracyclic azepine derivatives having affinity for 5-HT2 receptors | |
| CN1046281C (en) | Pharmacologically active enantiomers | |
| JP3721388B2 (en) | Novel medium-membered ring amine having surface asymmetry and process for producing the same | |
| WO2012147925A1 (en) | Method for producing five-membered ring-containing compound | |
| CN1040752C (en) | Novel piperidine derivatives and process for the preparation thereof | |
| CN1634928A (en) | Camptothecin derivatives preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |